37859-23-7

Basic information

• Product Name: Benzeneacetyl chloride, 4-hydroxy-
• Synonyms: Benzeneacetyl chloride, 4-hydroxy-
• CAS NO: 37859-23-7
• Molecular Formula: C₈H₇ClO₂
• Molecular Weight: 170.59298
• Mol File: 37859-23-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 296.2°C at 760 mmHg
• Flash Point: 133°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 0.000823mmHg at 25°C
• Refractive Index: 1.572
• PKA: 9.81±0.15(Predicted)
• CAS DataBase Reference: Benzeneacetyl chloride, 4-hydroxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetyl chloride, 4-hydroxy-(37859-23-7)
• EPA Substance Registry System: Benzeneacetyl chloride, 4-hydroxy-(37859-23-7)

Safety Data

• Hazardous Substances Data: 37859-23-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H7ClO2/c9-8(11)5-6-1-3-7(10)4-2-6/h1-4,10H,5H2

Upstream product

• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 116606-60-1 17-(4-hydroxy-phenethyl)-morphinan-3-ol 
• 130497-49-3 2-(4-Hydroxy-phenyl)-1-(2-pyrrolidin-1-ylmethyl-piperidin-1-yl)-ethanone 
• 115339-15-6 7-<(4-hydroxyphenyl)acetamido>-3-chloro-3-cephem-4-carboxylic acid 
• 52727-15-8 p-Hydroxybenzyldiazomethylketon 
• 131179-77-6 N-(3,5-dimethylphenyl)-4-hydroxyphenylacetamide 
• 52727-28-3 6-hydroxy-1,2,3,4-tetrahydronaphthalen-2-one 
• 20277-03-6 <4-Hydroxy-phenyl>acethydroxamsaeure 
• 20277-02-5 2-(4-hydroxyphenyl)acetatic acid hydrazide 

Relevant articles and documents

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.

Combating P-glycoprotein-mediated multidrug resistance with 10-O-phenyl dihydroartemisinin ethers in MCF-7 cells

A series of 10-β-phenyl ethers of dihydroartemisinin (DHA) with piperazine substitutions were synthesized with the goal of overcoming multidrug resistance in cancer therapy. These novel compounds exerted significant antiproliferative activities in breast

SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such diseases include, without limitation, neurological dysfunction such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders; emotional disorders; depression; bipolar disorder; obsessive-compulsive disorder; and other anxiety disorders.